Literature DB >> 1381923

Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum.

G G Nomikos1, G Damsma, D Wenkstern, H C Fibiger.   

Abstract

Bupropion is a novel atypical antidepressant that inhibits dopamine (DA) uptake. The present experiments investigated the effects of acute (10 mg/kg, twice daily for 2 days) and chronic (10 mg/kg, twice daily for 21 days) bupropion treatment on interstitial DA concentrations using simultaneous in vivo microdialysis in the nucleus accumbens (NAC) and striatum of awake freely moving rats. Compared to animals that had not previously been exposed to the drug, bupropion (25 mg/kg, IP) induced increases in extracellular DA were significantly enhanced in the NAC of the chronic but not the acute bupropion group. This effect was regionally selective, as it was not observed in the striatum. In accordance with previous reports, concurrent behavioral measurements indicated that the locomotor stimulant effects of bupropion were also enhanced in the chronic group. These results demonstrate that bupropion-induced behavioral sensitization is accompanied by a selective potentiation of the effects of this compound on interstitial DA concentrations in the NAC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381923

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  32 in total

Review 1.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

2.  Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.

Authors:  Neil E Paterson; Allison Fedolak; Berend Olivier; Taleen Hanania; Afshin Ghavami; Barbara Caldarone
Journal:  Pharmacol Biochem Behav       Date:  2010-03-25       Impact factor: 3.533

3.  Reduced Motivation in Perinatal Fluoxetine-Treated Mice: A Hypodopaminergic Phenotype.

Authors:  Edênia C Menezes; Relish Shah; Lindsay Laughlin; K Yaragudri Vinod; John F Smiley; Catarina Cunha; Andrea Balla; Henry Sershen; Francisco X Castellanos; André Corvelo; Cátia M Teixeira
Journal:  J Neurosci       Date:  2021-02-03       Impact factor: 6.167

4.  Effects of chronic antidepressant drug administration and electroconvulsive shock on activity of dopaminergic neurons in the ventral tegmentum.

Authors:  Charles H K West; Jay M Weiss
Journal:  Int J Neuropsychopharmacol       Date:  2010-05-19       Impact factor: 5.176

Review 5.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

6.  Pavlovian drug discrimination with bupropion as a feature positive occasion setter: substitution by methamphetamine and nicotine, but not cocaine.

Authors:  Jamie L Wilkinson; Chia Li; Rick A Bevins
Journal:  Addict Biol       Date:  2008-12-12       Impact factor: 4.280

7.  A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.

Authors:  Tatiana Lipina; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2009-12-16       Impact factor: 4.530

8.  Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain.

Authors:  P Hertel; G G Nomikos; M Iurlo; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

9.  Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice.

Authors:  Michel Bourin; Franck Chenu; Corina Prica; Martine Hascoët
Journal:  Psychopharmacology (Berl)       Date:  2009-06-11       Impact factor: 4.530

10.  Partial nicotinic acetylcholine (alpha4beta2) agonists as promising new medications for smoking cessation.

Authors:  J Singh; Salil Budhiraja
Journal:  Indian J Pharmacol       Date:  2008-10       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.